Bedrijfsoverzicht
vTv Therapeutics Inc. is a late-stage biopharmaceutical entity dedicated to the development of oral small molecule drug candidates designed to address conditions such as diabetes and other chronic diseases. The company operates within the healthcare sector, specifically the biotechnology industry, where its focus is on creating therapies that can be administered orally rather than via injection, aiming to improve patient compliance and quality of life. As of the latest available data, the company maintains a market capitalization of $144.00M and employs a workforce of 26 individuals to drive its research and development efforts. The market cap figure indicates that vTv Therapeutics is classified as a small-cap company, suggesting a limited scale relative to large-cap peers but offering potential for significant expansion if its lead candidates achieve clinical success. The absence of reported annual revenue in the provided metrics further contextualizes the company's position as an entity likely still in the pre-revenue or early commercialization phase, where capital allocation is heavily weighted toward R&D rather than sales operations. This operational scale and financial structure are typical for late-stage biopharmaceutical firms that have yet to generate substantial commercial income from their pipeline assets.
Financiële gezondheid
The financial statements for vTv Therapeutics Inc. report a Net Income (TTM) of $-26,974,000 and an EBITDA of $-32,792,000, while Revenue (TTM) and Price to Sales are listed as N/A. The significant disparity between the reported revenue gap and the substantial negative net income reveals a cost structure dominated by high research, development, and operational expenses that exceed any current revenue generation. The company reports Free Cash Flow of $-14,697,750, which indicates a continuous consumption of cash reserves to fund its operations and clinical trials, thereby limiting immediate financial flexibility until product approvals occur. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting a business model where costs are incurred before significant commercial sales volume is realized. On the liability side, the company holds Cash of $88.93M against zero reported Debt, resulting in a Debt to Equity ratio of N/A, which suggests a highly conservative balance sheet with no leveraged obligations. The Current Ratio stands at 13.54, a figure that indicates robust short-term liquidity and an ability to cover current liabilities many times over with existing current assets. Return on Equity is -78.9% and Return on Assets is -32.0%, metrics that reveal that management is currently generating negative returns on the capital invested, a common characteristic for biotechnology companies in the late-stage development phase before reaching profitability.
Waarderingsbeoordeling
The company's trailing P/E Ratio (TTM) is N/A due to negative earnings, while the Forward P/E is listed as -9.82, a metric that implies the market is pricing in future earnings that are not yet realized or are expected to remain negative in the short term. The Price to Book ratio is 7.04, indicating that the market values the company at a significant premium over its book value, likely reflecting the potential value of its intellectual property and drug pipeline rather than its current book assets. Alternative valuation metrics such as Price to Sales (N/A) and EV/EBITDA (-11.12) suggest that traditional multiple-based comparisons are not applicable, as the EV/EBITDA remains negative due to the company's lack of profitability. The stock has exhibited a trading range between a 52-Week High of $44.00 and a 52-Week Low of $14.00, placing the current valuation context within a broad band of volatility typical for biotech equities. The Beta value is 0.40, which signifies that the stock's price volatility is significantly lower than that of the broader market, implying that the asset may be less sensitive to general market fluctuations than large-cap stocks.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, meaning that historical growth rates cannot be calculated from the available fiscal data. In the absence of positive earnings, the concept of earnings growing faster or slower than revenue does not apply in a traditional sense, as the company is currently burning cash rather than compounding profits. As a non-dividend payer, the company does not distribute a Dividend Yield or maintain a Payout Ratio, both of which are N/A or 0.0%, indicating that all available resources are being reinvested into growth initiatives such as clinical trials and regulatory approvals rather than shareholder returns. This reinvestment strategy is standard for late-stage biopharmaceutical companies that prioritize capitalizing on their drug candidates over providing current income to shareholders. The overall growth and income profile is characterized by a lack of current profitability and dividend income, with the company's value proposition derived entirely from the potential future success of its oral small molecule drug candidates.